Walleye Capital LLC Buys Shares of 86,249 Eton Pharmaceuticals, Inc. $ETON

Walleye Capital LLC bought a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) in the second quarter, HoldingsChannel reports. The institutional investor bought 86,249 shares of the company’s stock, valued at approximately $3,122,000.

Several other institutional investors also recently made changes to their positions in ETON. Opaleye Management Inc. grew its stake in shares of Eton Pharmaceuticals by 0.3% during the 2nd quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company’s stock worth $40,755,000 after purchasing an additional 7,930 shares during the period. EcoR1 Capital LLC lifted its stake in shares of Eton Pharmaceuticals by 7.0% in the first quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock valued at $53,603,000 after purchasing an additional 141,394 shares during the period. Vanguard Group Inc. lifted its stake in shares of Eton Pharmaceuticals by 2.4% in the third quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock valued at $29,208,000 after purchasing an additional 31,942 shares during the period. State Street Corp boosted its holdings in Eton Pharmaceuticals by 14.5% during the fourth quarter. State Street Corp now owns 501,925 shares of the company’s stock worth $8,488,000 after buying an additional 63,480 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in Eton Pharmaceuticals by 156.3% during the first quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock worth $4,620,000 after buying an additional 217,042 shares in the last quarter. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider David Krempa sold 42,797 shares of the stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $33.39, for a total transaction of $1,428,991.83. Following the transaction, the insider directly owned 25,249 shares in the company, valued at $843,064.11. This represents a 62.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jennifer Mckie Adams sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the completion of the sale, the director owned 50,000 shares of the company’s stock, valued at approximately $1,624,000. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 150,000 shares of company stock worth $4,853,921. Corporate insiders own 16.49% of the company’s stock.

Eton Pharmaceuticals News Roundup

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Quarterly results significantly exceeded expectations: Eton reported adjusted earnings of approximately $0.35–$0.43 per share, compared with consensus estimates ranging from $0.11 to $0.15. Revenue reached $37.59 million, well above the $27.11 million analyst forecast, and the company improved from a loss in the year-ago period. Eton Pharmaceuticals Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Strong commercial growth supported the beat: Product sales nearly doubled year over year, increasing 99% in the second quarter. Management raised 2026 revenue guidance to more than $145 million and reiterated a long-term opportunity to generate over $500 million in peak annual sales through organic growth, pipeline products and acquisitions in rare diseases. Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Profitability expectations are improving: Eton expects adjusted EBITDA margins above 35% in 2026, potentially reaching 50% by 2028, while gross margins are projected to expand from roughly 70% to more than 75%. These targets reinforce the market’s view that revenue growth could translate into substantial earnings growth. Eton Pharmaceuticals: No Reason Pharma Can’t Deliver More Great Earnings Like These
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $65 price target, suggesting continued upside potential, although its estimates imply investors will be focused on whether Eton can sustain the pace of growth.
• Negative Sentiment: HC Wainwright reduced its long-term EPS forecasts for 2027–2030, including lowering its 2030 estimate to $6.53 from $8.65. The revisions create a counterpoint to the upbeat quarterly results and highlight execution and valuation risks after the stock’s rapid advance. HC Wainwright Issues Negative Outlook for ETON Earnings

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Friday, July 17th. Craig Hallum boosted their price target on Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Zacks Research lowered Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Canaccord Genuity Group upped their price target on Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a report on Friday. Finally, Wall Street Zen raised Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. Four analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Eton Pharmaceuticals currently has an average rating of “Hold” and an average target price of $67.50.

Eton Pharmaceuticals Stock Up 44.3%

ETON opened at $58.86 on Friday. The firm has a market cap of $1.61 billion, a P/E ratio of 154.89 and a beta of 0.86. The business’s fifty day simple moving average is $39.06 and its 200 day simple moving average is $28.59. Eton Pharmaceuticals, Inc. has a 52 week low of $14.27 and a 52 week high of $59.79. The company has a quick ratio of 0.88, a current ratio of 1.21 and a debt-to-equity ratio of 0.62.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings data on Thursday, August 13th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.32. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 47.64%. The business had revenue of $37.59 million for the quarter, compared to the consensus estimate of $27.11 million. As a group, equities research analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.67 EPS for the current fiscal year.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.